Delphian Therapeutics' Cannabinoid Migraine Research Named Editor's Choice in the Journal of the International Headache Society

Feb 2025

Being selected for Editor’s Choice underscores the originality and scientific significance of this research within the field of headache medicine.

Delphian Therapeutics is pleased to announce that research underpinning its migraine therapeutic program has been selected as the Editor's Choice for February 2025 in Cephalalgia, the Journal of the International Headache Society.

The paper, titled "Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like symptoms in mice," was authored by E. Zorrilla and colleagues. Being selected for Editor's Choice underscores the originality and scientific significance of this research within the field of headache medicine.

The study investigates the effects of combined CBD and THC on migraine-like symptoms in preclinical models, presenting innovative approaches in cannabinoid-based migraine research.

Cephalalgia is one of the leading peer-reviewed journals in the headache and migraine research field, and the Editor's Choice designation is reserved for work the editorial board considers particularly noteworthy.

The article is published in Cephalalgia, Volume 45, Issue 2, 2025. DOI: 10.1177/03331024251314487

View the Cephalalgia Editor's Choice page on the International Headache Society website.